Abstract
A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo–generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Banchereau, J. et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451–6458 (2001).
Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328–332 (1998).
Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669–1678 (1999).
Chang, A.E. et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021–1032 (2002).
Timmerman, J.M. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517–1526 (2002).
Murphy, G.P. et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39, 54–59 (1999).
Nair, S.K. et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235, 540–549 (2002).
Kugler, A. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332–336 (2000).
Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809–8814 (2001).
Eggert, A.A. et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59, 3340–3345 (1999).
Cayeux, S. et al. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol. 29, 225–234 (1999).
Borrello, I.M. & Sotomayor, E.M. Cancer vaccines for hematologic malignancies. Cancer Control 9, 138–151 (2002).
Teshima, T. et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61, 162–171 (2001).
Anderson, L.D., Jr., Savary, C.A. & Mullen, C.A. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 95, 2426–2433 (2000).
Asavaroengchai, W., Kotera, Y. & Mule, J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99, 931–936 (2002).
Cui, Y. et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99, 399–408 (2002).
Woods, N.B., Ooka, A. & Karlsson, S. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia 16, 563–569 (2002).
Lynch, D.H. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev. Immunol. 18, 99–107 (1998).
Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774–779 (1999).
Sotomayor, E.M. et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780–787 (1999).
Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178–1183 (1998).
Mackall, C.L. et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 156, 4609–4616 (1996).
Borrello, I. et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011–3019 (2000).
Merad, M., Sugie, T., Engleman, E.G. & Fong, L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99, 1676–1682 (2002).
Borges, L. et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163, 1289–1297 (1999).
Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233–238 (2001).
Whartenby, K.A. et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 100, 3147–3154 (2002).
Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Meth. 145, 185–192 (1991).
Acknowledgements
We thank L. Domina for administrative assistance. This research was supported by gifts from Dorothy Needle, Bill & Betty Topercer and the Goodwin Foundation. D.P. is a Janey scholar and holds the Seraph chair in Oncology. C.C. holds the Herman and Walter Samuelson chair in Oncology. H.L. was supported by CA96888-01.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cui, Y., Kelleher, E., Straley, E. et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells. Nat Med 9, 952–958 (2003). https://doi.org/10.1038/nm882
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/nm882
This article is cited by
-
Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells
Cancer Gene Therapy (2008)
-
Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin
Nature (2007)
-
Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy
Molecular Therapy (2007)
-
T cells with potential to target metastatic cells
Nature Reviews Cancer (2005)
-
New directions for tumour therapy
Nature Reviews Cancer (2003)
